Results 191 to 200 of about 34,140,631 (244)

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis. [PDF]

Gastroenterology Res
Ahmed Z, Iqbal A, Ghazaleh S, Kobeissy A, Nawras A, Alastal Y, Saad H, Mansur S, Mohiuddin I, Iqbal U, Dahiya DS, Arif SF, Campbell C, Lee-Smith W, Asif MW, Kamal F, Saeed A, Horani O.   +17 more
europepmc   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du, Giselle Sarganas, Beate Gaertner, Maike Buchmann, Judith Fuchs, Hannelore Neuhauser, Christin Heidemann   +6 more
wiley   +1 more source

Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy

American Journal of Preventive Cardiology
Harshvir S. Bal, Amrita Nayak, Akhil Pampana, Sindhoosha Malay, Astha Upadhyaya, Nehal Vekariya, Garima Arora, Pankaj Arora   +7 more
doaj   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats. [PDF]

Behav Pharmacol
Evans B, Acharya N, Brandl CG, Shealy EG, Nyland JE, Freet CS, Bunce SC, Grigson PS.   +7 more
europepmc   +1 more source

Association of glucagon-like peptide-1 receptor agonist use with patient-reported outcomes after lumbar decompression or fusion. [PDF]

N Am Spine Soc J
Parker J, Brennan J, Johnson A, Peterman M, Patton C, Turcotte J.   +5 more
europepmc   +1 more source

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials.
Giacomo Ruotolo, Charles Harris, Yanzhu Lin, Jonathan M. Wilson, Valentina Pirro, Kevin L. Duffin, Melissa K. Thomas, Mark L. Hartman, Ciara O' Neill, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Naveed Sattar, Stephen J. Nicholls   +13 more
wiley   +1 more source